{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:01:43Z","timestamp":1777730503731,"version":"3.51.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.humimm.2024.111161","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T17:49:18Z","timestamp":1729792158000},"page":"111161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Decoy oligodeoxynucleotides: A promising therapeutic strategy for inflammatory skin disorders"],"prefix":"10.1016","volume":"85","author":[{"given":"Maryam","family":"Mahjoubin-Tehran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samaneh","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sercan","family":"Karav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.humimm.2024.111161_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a040840","article-title":"Building and maintaining the skin","volume":"14","author":"Hsu","year":"2022","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0010","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1590\/abd1806-4841.20165577","article-title":"Inflammasomes and dermatology","volume":"91","author":"S\u00e1","year":"2016","journal-title":"An. Bras. Dermatol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111161_b0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/ijms24010837","article-title":"Is atopic dermatitis only a skin disease?","volume":"24","author":"Mesjasz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0020","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/bjd.14697","article-title":"Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults","volume":"175","author":"Strom","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.humimm.2024.111161_b0025","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/jid.2015.337","article-title":"Association between atopic dermatitis and depression in US adults","volume":"135","author":"Sherry","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"10","key":"10.1016\/j.humimm.2024.111161_b0030","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/all.12685","article-title":"Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies","volume":"70","author":"Silverberg","year":"2015","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2133.2011.10694.x","article-title":"Association between atopic dermatitis and obesity in adulthood","volume":"166","author":"Silverberg","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.111161_b0040","series-title":"Comorbidities in psoriasis patients. Seminars in cutaneous medicine and surgery","year":"2010"},{"issue":"1","key":"10.1016\/j.humimm.2024.111161_b0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin. Dermatol."},{"issue":"14","key":"10.1016\/j.humimm.2024.111161_b0050","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0055","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Fuxench","year":"2019","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.humimm.2024.111161_b0060","series-title":"Quality of life in patients with psoriasis: a systematic literature review","year":"2004"},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0065","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","article-title":"Determinants of quality of life in patients with psoriasis: a study from the US population","volume":"51","author":"Gelfand","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public health burden and epidemiology of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.humimm.2024.111161_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of skin resident memory T cells","volume":"11","author":"Tokura","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111161_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021564","article-title":"Exploring mast Cell\u2013CD8 T cell interactions in inflammatory skin diseases","volume":"24","author":"Chen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0085","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/cells9030531","article-title":"Memory CD4+ T cells in immunity and autoimmune diseases","volume":"9","author":"Raphael","year":"2020","journal-title":"Cells."},{"key":"10.1016\/j.humimm.2024.111161_b0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-319-68617-2_14","article-title":"Mechanisms of allergic contact dermatitis","author":"Rustemeyer","year":"2020","journal-title":"Kanerva\u2019s Occup. Dermatol."},{"issue":"8","key":"10.1016\/j.humimm.2024.111161_b0095","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41409-022-01713-7","article-title":"Allogeneic transplantation in Cutaneous T-cell lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease","volume":"57","author":"Angelov","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.humimm.2024.111161_b0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev-immunol-082919-093554","article-title":"Innate lymphocyte mechanisms in skin diseases","volume":"38","author":"Chen","year":"2020","journal-title":"Annu. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.humimm.2024.111161_b0105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41577-019-0162-3","article-title":"T cells and the skin: from protective immunity to inflammatory skin disorders","volume":"19","author":"Ho","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.humimm.2024.111161_b0110","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41590-023-01607-w","article-title":"Cardinal features of immune memory in innate lymphocytes","volume":"24","author":"Santosa","year":"2023","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111161_b0115","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.drudis.2019.10.008","article-title":"Decoy oligodeoxynucleotide technology: an emerging paradigm for breast cancer treatment","volume":"25","author":"Mahjoubin-Tehran","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"6995","key":"10.1016\/j.humimm.2024.111161_b0120","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nature02698","article-title":"Evolutionary changes in cis and trans gene regulation","volume":"430","author":"Wittkopp","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.humimm.2024.111161_b0125","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1186\/s12864-019-6342-5","article-title":"Evolution of cis- and trans-regulatory divergence in the chicken genome between two contrasting breeds analyzed using three tissue types at one-day-old","volume":"20","author":"Wang","year":"2019","journal-title":"BMC Genomics"},{"issue":"7","key":"10.1016\/j.humimm.2024.111161_b0130","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.drudis.2021.04.004","article-title":"Decoys as potential therapeutic tools for diabetes","volume":"26","author":"Mahjoubin-Tehran","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.humimm.2024.111161_b0135","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/nar\/30.11.2435","article-title":"Design and characterization of decoy oligonucleotides containing locked nucleic acids","volume":"30","author":"Crinelli","year":"2002","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.humimm.2024.111161_b0140","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.humimm.2024.111161_b0145","doi-asserted-by":"crossref","DOI":"10.2174\/0929867330666230505154319","article-title":"Therapeutic potential of decoys for prostate cancers: a review of recent updates","author":"Rezaei","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.humimm.2024.111161_b0150","article-title":"Harnessing the therapeutic potential of decoys in non-atherosclerotic cardiovascular diseases: state of the art","volume":"8","author":"Mahjoubin-Tehran","year":"2021","journal-title":"J. Cardiovasc. Devel. Dis. [Internet]"},{"issue":"9","key":"10.1016\/j.humimm.2024.111161_b0155","article-title":"Decoy technology as a promising therapeutic tool for atherosclerosis","volume":"22","author":"Mahjoubin-Tehran","year":"2021","journal-title":"Int. J. Mol. Sci. [Internet]"},{"issue":"4","key":"10.1016\/j.humimm.2024.111161_b0160","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14656566.2021.1999412","article-title":"The evolving atopic dermatitis management landscape","volume":"23","author":"Sahni","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.humimm.2024.111161_b0165","series-title":"Topical corticosteroids: use and adverse effects","author":"Goldstein","year":"2022"},{"issue":"4","key":"10.1016\/j.humimm.2024.111161_b0170","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","article-title":"Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council","volume":"147","author":"Renert-Yuval","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0175","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00011-023-01690-7","article-title":"Eosinophilia and elevated IgE serum levels: a red flag: when your diagnosis is not a common atopic eczema or common allergy","volume":"72","author":"Criado","year":"2023","journal-title":"Inflamm. Res."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100519","article-title":"Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence","volume":"14","author":"Wollenberg","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.humimm.2024.111161_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1214963","article-title":"Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents","volume":"10","author":"Caffarelli","year":"2023","journal-title":"Front. Med."},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0190","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s13555-023-00920-4","article-title":"Emerging systemic treatments for atopic dermatitis","volume":"13","author":"Ferrucci","year":"2023","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"2","key":"10.1016\/j.humimm.2024.111161_b0195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2177\/jsci.35.107","article-title":"A Decoy Oligodeoxynucleotides therapy for allergic skin diseases","volume":"35","author":"Yokozeki","year":"2012","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.humimm.2024.111161_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102036","article-title":"The decoy oligodeoxynucleotide against HIF-1\u03b1 and STAT5 ameliorates atopic dermatitis-like mouse model","volume":"34","author":"Gwon","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1\u20132","key":"10.1016\/j.humimm.2024.111161_b0205","first-page":"127","article-title":"Potential use of iontophoresis for transdermal delivery of NF-kappaB decoy oligonucleotides","volume":"393","author":"Hashim","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.humimm.2024.111161_b0210","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/sj.jid.5700307","article-title":"Blockade of experimental atopic dermatitis via topical NF-kappaB decoy oligonucleotide","volume":"126","author":"Dajee","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"18","key":"10.1016\/j.humimm.2024.111161_b0215","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.gt.3301724","article-title":"Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC\/Nga atopic mouse model","volume":"9","author":"Nakamura","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.humimm.2024.111161_b0220","series-title":"Development and first clinical trial of NFkB decoy DNA ointment for treatment of severe atopic dermatitis patients in Japan. MOLECULAR THERAPY","year":"2003"},{"issue":"22","key":"10.1016\/j.humimm.2024.111161_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216095","article-title":"Inflammation and psoriasis: a comprehensive review","volume":"24","author":"Man","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.111161_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.649408","article-title":"Cutaneous and systemic psoriasis: classifications and classification for the distinction","volume":"8","author":"Yan","year":"2021","journal-title":"Front. Med."},{"issue":"17","key":"10.1016\/j.humimm.2024.111161_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.humimm.2024.111161_b0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2020.04.044","article-title":"Non-invasive delivery of biological macromolecular drugs into the skin by iontophoresis and its application to psoriasis treatment","volume":"323","author":"Fukuta","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.humimm.2024.111161_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120601","article-title":"Overcoming thickened pathological skin in psoriasis via iontophoresis combined with tight junction-opening peptide AT1002 for intradermal delivery of NF-\u03baB decoy oligodeoxynucleotide","volume":"602","author":"Fukuta","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050678","article-title":"An updated review of hypertrophic scarring","volume":"12","author":"Mony","year":"2023","journal-title":"Cells."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0255","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23225","article-title":"Hypoxia-inducible factor-1\u03b1 activates transforming growth factor-\u03b21\/Smad signaling and increases collagen deposition in dermal fibroblasts","volume":"9","author":"Mingyuan","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.humimm.2024.111161_b0260","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.3892\/mmr.2020.11549","article-title":"Smad-binding decoy reduces extracellular matrix expression in human hypertrophic scar fibroblasts","volume":"22","author":"Fan","year":"2020","journal-title":"Mol. Med. Rep."},{"issue":"24","key":"10.1016\/j.humimm.2024.111161_b0265","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/sj.gt.3302341","article-title":"In vivo transfection of a cis element 'decoy' against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model","volume":"11","author":"Yokozeki","year":"2004","journal-title":"Gene Ther."},{"issue":"15","key":"10.1016\/j.humimm.2024.111161_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155382","article-title":"Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis","volume":"21","author":"Furue","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"46","key":"10.1016\/j.humimm.2024.111161_b0275","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1038\/sj.onc.1204629","article-title":"Induction of the IL-13 receptor \u03b12-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways","volume":"20","author":"David","year":"2001","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0280","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.alit.2018.12.011","article-title":"STAT6 decoy oligodeoxynucleotide (ODN)-containing ointment more potently inhibits mouse skin inflammation when formulated with ionic liquid technology than as a traditional Vaseline ointment","volume":"68","author":"Handa","year":"2019","journal-title":"Allergol. Int."},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0285","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1365-2133.2009.09070.x","article-title":"A therapeutic effect of STAT6 decoy oligodeoxynucleotide ointment in atopic dermatitis: a pilot study in adults","volume":"160","author":"Igawa","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"24","key":"10.1016\/j.humimm.2024.111161_b0290","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.gt.3302345","article-title":"In vivo transfection of a cis element 'decoy' against signal transducers and activators of the transcription 6 (STAT6) binding site ameliorates the response of contact hypersensitivity","volume":"11","author":"Sumi","year":"2004","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0295","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/157436209789057467","article-title":"Targeting JAK\/STAT signaling pathway in inflammatory diseases","volume":"4","author":"Malemud","year":"2009","journal-title":"Curr. Signal Transduct. Ther."},{"issue":"1","key":"10.1016\/j.humimm.2024.111161_b0300","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaci.2007.09.015","article-title":"Signal transducer and activator of transcription 1 decoy oligodeoxynucleotide suppression of contact hypersensitivity","volume":"121","author":"Wagner","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2024.111161_b0305","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1089\/ars.2013.5653","article-title":"Damage to skin extracellular matrix induced by UV exposure","volume":"21","author":"Watson","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.humimm.2024.111161_b0310","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdcr.2023.03.023","article-title":"Cutaneous graft-versus-host disease within chronic photodamaged skin: a case series demonstrating role for topical 5-fluorouracil","volume":"36","author":"Gray","year":"2023","journal-title":"JAAD Case Reports."},{"issue":"Suppl 2","key":"10.1016\/j.humimm.2024.111161_b0315","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2133.2005.06969.x","article-title":"Enhancement of ultraviolet-induced apoptosis by NF-kappaB decoy oligonucleotides","volume":"153","author":"Yokoyama","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.humimm.2024.111161_b0320","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-662-11196-3_12","article-title":"Types I, II, III, and IV hypersensitivity","author":"Cruse","year":"1999","journal-title":"Atlas Immunol."},{"key":"10.1016\/j.humimm.2024.111161_b0325","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2019.1602435","article-title":"The vaccines-associated Arthus reaction","author":"Peng","year":"2019","journal-title":"Hum. Vaccin. Immunotherap."},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0330","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s002100100472","article-title":"Transcription factor decoy oligodeoxynucleotides to nuclear factor-kappaB inhibit reverse passive Arthus reaction in rat","volume":"364","author":"D'Acquisto","year":"2001","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.humimm.2024.111161_b0335","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2017.06.122","article-title":"Transcription factor decoy technology: A therapeutic update","volume":"144","author":"Hecker","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.humimm.2024.111161_b0340","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1007\/s13277-015-3344-z","article-title":"Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer","volume":"36","author":"Rad","year":"2015","journal-title":"Tumor Biol."},{"issue":"8","key":"10.1016\/j.humimm.2024.111161_b0345","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-12-0191","article-title":"First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy","volume":"2","author":"Sen","year":"2012","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.humimm.2024.111161_b0350","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/10717544.2017.1370511","article-title":"Suppression of chronic inflammation with engineered nanomaterials delivering nuclear factor \u03baB transcription factor decoy oligodeoxynucleotides","volume":"24","author":"Farahmand","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.humimm.2024.111161_b0355","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jconrel.2015.09.017","article-title":"Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges","volume":"219","author":"Zakrewsky","year":"2015","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.humimm.2024.111161_b0360","first-page":"57","article-title":"Topical delivery of nucleic acids in the skin","volume":"11","author":"Preat","year":"2001","journal-title":"STP Pharma Sci."},{"issue":"11","key":"10.1016\/j.humimm.2024.111161_b0365","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ejcb.2010.07.010","article-title":"Tight junctions form a barrier in human epidermis","volume":"89","author":"Kirschner","year":"2010","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.humimm.2024.111161_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122005","article-title":"In silico and experimental validation of a new modified arginine-rich cell penetrating peptide for plasmid DNA delivery","volume":"624","author":"Mahjoubin-Tehran","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.humimm.2024.111161_b0375","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-642-54452-1_13","article-title":"Challenges and opportunities for oligonucleotide-based therapeutics by antisense and RNA interference mechanisms","author":"Eritja","year":"2014","journal-title":"Chem. Biol. Nucleic Acids Fundam. Clin. Appl."},{"issue":"12","key":"10.1016\/j.humimm.2024.111161_b0380","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt.3078","article-title":"Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications","volume":"32","author":"Meade","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.humimm.2024.111161_b0385","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ymthe.2017.03.009","article-title":"Non-invasive oil-based method to increase topical delivery of nucleic acids to skin","volume":"25","author":"Vij","year":"2017","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.humimm.2024.111161_b0390","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4155\/tde.15.39","article-title":"Recent developments in silicones for topical and transdermal drug delivery","volume":"6","author":"Aliyar","year":"2015","journal-title":"Ther. Deliv."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0395","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jconrel.2007.05.031","article-title":"Transdermal delivery enhanced by magainin pore-forming peptide","volume":"122","author":"Kim","year":"2007","journal-title":"J. Control. Release"},{"issue":"38","key":"10.1016\/j.humimm.2024.111161_b0400","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1073\/pnas.1016152108","article-title":"Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer","volume":"108","author":"Hsu","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.humimm.2024.111161_b0405","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1172\/JCI11459","article-title":"Therapeutic applications of transcription factor decoy oligonucleotides","volume":"106","author":"Mann","year":"2000","journal-title":"J. Clin. Invest."},{"issue":"21","key":"10.1016\/j.humimm.2024.111161_b0410","doi-asserted-by":"crossref","first-page":"11421","DOI":"10.1073\/pnas.93.21.11421","article-title":"Fusigenic viral liposome for gene therapy in cardiovascular diseases","volume":"93","author":"DzAu","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"18","key":"10.1016\/j.humimm.2024.111161_b0415","doi-asserted-by":"crossref","first-page":"8474","DOI":"10.1073\/pnas.90.18.8474","article-title":"Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia","volume":"90","author":"Morishita","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0420","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0005-2760(96)00126-9","article-title":"Interaction of liposomes with human skin in vitro\u2014the influence of lipid composition and structure","volume":"1304","author":"Kirjavainen","year":"1996","journal-title":"Biochim. Biophys. Acta (BBA)-Lipids Lipid Metab."},{"issue":"2","key":"10.1016\/j.humimm.2024.111161_b0425","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0006-3495(03)74917-0","article-title":"Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier","volume":"84","author":"Cevc","year":"2003","journal-title":"Biophys. J."},{"issue":"3","key":"10.1016\/j.humimm.2024.111161_b0430","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10215","article-title":"Formulation-based approaches for dermal delivery of vaccines and therapeutic nucleic acids: recent advances and future perspectives","volume":"6","author":"Sallam","year":"2021","journal-title":"Bioeng. Transl. Med."},{"issue":"6","key":"10.1016\/j.humimm.2024.111161_b0435","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/gt.2010.32","article-title":"Pre-clinical evaluation of liposomal gene transfer to improve dermal and epidermal regeneration","volume":"17","author":"Branski","year":"2010","journal-title":"Gene Ther."},{"issue":"30","key":"10.1016\/j.humimm.2024.111161_b0440","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6049","article-title":"Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations","volume":"6","author":"Mandal","year":"2020","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0445","article-title":"Development and first clinical trial of NFkB decoy DNA ointment for treatment of severe atopic dermatitis patients in Japan","volume":"7","author":"Tamai","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.humimm.2024.111161_b0450","article-title":"Pathophysiology of atopic dermatitis and psoriasis: implications for management in children","volume":"6","author":"Chovatiya","year":"2019","journal-title":"Children (Basel)"},{"issue":"17","key":"10.1016\/j.humimm.2024.111161_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2340\/00015555-3653","article-title":"Impact of atopic dermatitis in adolescents and their parents: a French study","volume":"100","author":"Ezzedine","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.humimm.2024.111161_b0460","series-title":"Atopic Dermatitis-Eczema: Clinics, Pathophysiology and Therapy","first-page":"81","article-title":"Etiopathophysiology of atopic eczema","author":"Eyerich","year":"2023"},{"issue":"5","key":"10.1016\/j.humimm.2024.111161_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100799","article-title":"Chronic systemic inflammatory skin disease as a risk factor for cardiovascular disease","volume":"46","author":"Bulger","year":"2021","journal-title":"Curr. Probl. Cardiol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:35:13Z","timestamp":1733880913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924004245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0198885924004245"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111161","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoy oligodeoxynucleotides: A promising therapeutic strategy for inflammatory skin disorders","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111161"}}